Xiangjun Kong is an accomplished Associate Director at AstraZeneca since January 2025, following a five-year tenure at Neogene Therapeutics as a Principal Scientist, Senior Scientist, and Scientist from January 2020 to January 2025. Prior to this, experience includes a Postdoctoral Fellowship at The Netherlands Cancer Institute from October 2013 to December 2019, where Xiangjun Kong utilized high-throughput genetic screening to investigate mechanisms of cancer drug addiction and immunotherapy resistance. Academic credentials include a Doctor of Philosophy (PhD) in Cell/Cellular and Molecular Biology from the University of Science and Technology of China (2007-2013) and a Bachelor's degree in Tea Science from Anhui Agricultural University (2003-2007).
This person is not in the org chart
This person is not in any teams
This person is not in any offices